.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,106,869

« Back to Dashboard

Details for Patent: 5,106,869

Title: Prostaglandins of the F series
Abstract:The present invention provides new compounds, 13,14-dihydro-15-keto-PGFs, and vassopressors containing them, which raise blood pressure without substantial ephemeral depression of blood pressure, trachea or enteron contraction effect inherent in usual PGFs.
Inventor(s): Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuji (Nishinomiya, JP), Oda; Tomio (Itami, JP)
Assignee: K.K. Ueno Seiyaku Oyo Kenkyujo (Osaka, JP)
Filing Date:Sep 07, 1990
Application Number:07/579,116
Claims:1. A process for providing a vasopressor effect to a patient in need of said effect which comprises administering to said patient a vasopressor effective amount of a 13,14-dihydro-15-keto-PGF represented by the general formula:

in which a bond between C-2 and C-3 is a single or a double bond; X represents a group selected from ##STR37## R.sub.1 is a hydrogen atom or a C.sub.1-4 alkyl, phenyl, benzoyl, hydroxyalkyl, alkoxyalkyl, trialkylsilyl or tetrahydropyranyl group; R.sub.2 is a hydrogen atom or a lower alkyl group; R.sub.3 is a hydroxyl group and R.sub.3 ' is hydroxyl, methyl or hydroxymethyl; R.sub.4 and R.sub.5 are the same or different, and signify a hydrogen atom, a halogen atom, or a lower alkyl group; and R.sub.6 is a C.sub.4-9 alkyl which may or may not be branched or contain a double bond or an alkoxy, or a group of the general formula: ##STR38## (Y indicates a bond or an oxygen atom; R.sub.7 indicates a hydrogen or halogen atom or a halogenated alkyl group); with the proviso that when R.sub.6 is n-butyl, at least one of R.sub.1, R.sub.2, R.sub.4 and R.sub.5 is not a hydrogen atom, and physiologically acceptable salts thereof.

2. The process of claim 1, wherein R.sub.1 is an alkyl group having a carbon number of one to four.

3. The process of claim 1, wherein R.sub.3 and/or R.sub.3 ' are a methyl.

4. The process of claim 1, wherein at least one of R.sub.4 and R.sub.5 is a halogen atom.

5. The process of claim 1, wherein at least one of R.sub.4 and R.sub.5 is a lower alkyl group.

6. The process of claim 1, wherein R.sub.6 is an alkyl group having a carbon number of four to six.

7. The process of claim 1, wherein R.sub.6 is a straight-chain alkyl group having a carbon number of six.

8. The process of claim 1, wherein R.sub.6 is a group of the general formula: ##STR39## wherein Y is a bond or an oxygen atom; R.sub.7 is a hydrogen atom, halogen atom or a halogenated alkyl group.

9. The process of claim 1, wherein X is ##STR40##

10. The process of claim 1, wherein each of R.sub.4 and R.sub.5 is a lower alkyl group.

11. The process of claim 1, wherein each of R.sub.4 and R.sub.5 is a halogen atom.

12. The process of claim 1, wherein R.sub.6 is a group of the general formula ##STR41## (Y indicates a bond or an oxygen atom; R.sub.7 indicates a hydrogen or halogen atom or a halogenated alkyl group).

13. The process of claim 1, wherein the PGF is selected from the group consisting of 13,14-dihydro-15-keto-16-phenoxy-PGFs.

14. The process of claim 1, wherein the PGF is selected from the group consisting of 13,14-dihydro-15-keto-16-desbutyl-16-trifluoromethyl-phenoxy-PGFs.

15. The process of claim 1, wherein R.sub.6 is a C.sub.5-9 alkyl chain which is a straight-chain.

16. The process of claim 1, wherein the PGF contains a C.sub.1-4 alkyl group at the 20-position.

17. The process of claim 16, wherein said alkyl group at the 20-position is an ethyl group.

18. The process of claim 1, wherein said compounds are PGF.sub.2 .alpha. compounds.

19. The process of claim 17, wherein the PGF is 13,14-dihydro-15-keto-16,R,S-fluoro-PGF.sub.2 .alpha.-methyl ester.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc